Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RIMIDUCID in Clinical Trials: A Safety Switch for Cellular Therapies

2 / 2
trials open to patients / all trials
1+
Countries

About the substance

Rimiducid: A Safety Switch Medication for Advanced Cellular Therapies

Table of Contents

What is Rimiducid?

Rimiducid (also known by its alternative name AP1903) is not a standard anti-cancer drug but rather a specialized medication designed to work as a "safety switch" in certain cellular therapies. It is administered to patients who have received genetically modified cells as part of their treatment for various conditions, particularly blood cancers and other disorders[1].

Rimiducid serves as a critical safety mechanism in advanced cellular therapies. When patients receive genetically modified cells (such as T cells), these cells are engineered to include a self-destruct mechanism called a "safety switch" or "suicide gene." If these modified cells cause severe side effects like Graft-versus-Host Disease (GvHD), rimiducid can be administered to activate this safety switch, causing the problematic cells to self-destruct through a process called apoptosis[2].

This innovative approach allows doctors to have better control over cellular therapies, potentially making these treatments safer for patients.

How Rimiducid Works

Rimiducid functions through a precise molecular mechanism targeting genetically modified cells:

  1. Activation of the Safety Switch: Rimiducid is administered intravenously, typically at doses of 0.4 mg/kg, though lower doses (0.1 mg/kg and 0.05 mg/kg) are also being investigated in some trials[3].

  2. Inducing Apoptosis: Once administered, rimiducid binds to a special protein called inducible caspase 9 (iCasp9) that has been engineered into the modified cells. This binding causes the protein to activate, triggering a cascade of cellular events that lead to apoptosis (programmed cell death) of the modified cells[4].

  3. Targeted Cell Elimination: This mechanism allows for selective elimination of only the genetically modified cells that contain the safety switch, while leaving other healthy cells in the body unaffected[5].

The beauty of this system is its specificity - rimiducid only affects cells that have been specifically engineered to respond to it, providing a precise way to control cellular therapies if they begin causing harmful side effects.

Medical Conditions Treated with Rimiducid

Rimiducid is not a primary treatment for any disease but rather acts as a safety component in cellular therapies for various conditions. Based on clinical trial data, these conditions include:

Blood Cancers

  • Acute Lymphoblastic Leukemia (ALL): A cancer of lymphocyte blood cells that affects both children and adults[6].
  • Acute Myeloid Leukemia (AML): A cancer of the myeloid line of blood cells characterized by rapid growth of abnormal white blood cells[7].
  • Non-Hodgkin Lymphoma: A group of blood cancers that includes all types of lymphoma except Hodgkin lymphomas[8].
  • Multiple Myeloma: A cancer of plasma cells that accumulate in the bone marrow[9].
  • Myelodysplastic Syndromes (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells[10].

Solid Tumors

  • Metastatic Prostate Cancer: Advanced prostate cancer that has spread to other parts of the body[11].
  • Various Advanced Solid Tumors: Including breast cancer, colorectal cancer, and others in experimental treatments[12].

Non-Malignant Conditions

  • Primary Immunodeficiency Disorders: Inherited conditions that affect the immune system[13].
  • Hemoglobinopathies: Genetic disorders affecting hemoglobin structure, such as sickle cell anemia[14].
  • Aplastic Anemia: A condition where the body stops producing enough new blood cells[15].
  • Inherited Metabolic Disorders: Conditions where the body cannot properly convert food to energy[16].
  • Systemic Lupus Erythematosus (SLE): An autoimmune disease in which the immune system attacks the body's tissues and organs[17].

Rimiducid in CAR-T Cell Therapy

Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of immunotherapy where a patient's T cells are modified to better recognize and attack cancer cells. Rimiducid plays a crucial role in enhancing the safety of these advanced treatments.

How CAR-T Cell Therapy Works with Rimiducid

In CAR-T cell therapy with rimiducid safety systems:

  1. T Cell Collection: Doctors collect T cells from the patient's blood through a process called apheresis[18].

  2. Genetic Modification: These T cells are genetically modified in a laboratory to express:

    • A chimeric antigen receptor (CAR) that targets specific proteins on cancer cells
    • A safety switch gene (often the inducible caspase 9 or iCasp9 gene) that responds to rimiducid[19]

  3. Cell Expansion: The modified T cells are grown in large numbers in the laboratory.

  4. Infusion: The patient receives the modified CAR-T cells through an IV infusion.

  5. Monitoring and Safety Management: If the patient develops severe side effects from the CAR-T cells (such as cytokine release syndrome or neurotoxicity), rimiducid can be administered to activate the safety switch and eliminate some or all of the CAR-T cells[20].

Examples of CAR-T Products Using Rimiducid

Several experimental CAR-T products incorporate rimiducid-responsive safety switches, including:

  • P-BCMA-ALLO1: Targets B-cell maturation antigen in multiple myeloma[21].
  • P-CD19CD20-ALLO1: Targets CD19 and CD20 proteins in B-cell malignancies[22].
  • P-PSMA-101: Targets prostate-specific membrane antigen in prostate cancer[23].
  • BPX-601: Targets PSCA (prostate stem cell antigen) in solid tumors[24].
  • P-MUC1C-ALLO1: Targets MUC1C in various solid tumors[25].

Rimiducid in Stem Cell Transplantation

Stem cell transplantation is a procedure in which healthy blood-forming stem cells are used to replace damaged or diseased bone marrow. Rimiducid has been extensively studied in the context of haploidentical (partially matched) stem cell transplants.

Role in Haploidentical Transplants

In haploidentical transplants, the donor is only a partial match to the recipient (often a parent, child, or sibling). This type of transplant carries a higher risk of Graft-versus-Host Disease (GvHD), where the donor cells attack the recipient's body[26].

Researchers have developed a system where:

  1. T Cell Depletion: The donor stem cell graft is depleted of certain T cells (TCR αβ+ T cells) that can cause GvHD.

  2. Addition of Modified T Cells: The patient receives the donor's stem cells along with donor T cells that have been genetically modified to include a rimiducid-responsive safety switch (these modified T cells are sometimes called rivogenlecleucel or BPX-501)[27].

  3. Safety Monitoring: If the patient develops GvHD despite the T cell depletion, rimiducid can be administered to eliminate the modified T cells and stop the GvHD[28].

This approach potentially allows patients to benefit from the positive effects of donor T cells (faster immune recovery, protection against infections, and anti-cancer effects) while providing a safety mechanism if GvHD occurs.

Safety Profile and Side Effects

Rimiducid itself appears to have a favorable safety profile, with most adverse events related to the underlying cellular therapy rather than the rimiducid administration.

Common Side Effects

When rimiducid is administered, patients may experience:

  • Fever: A temporary increase in body temperature[29].
  • Chills: Feeling cold and shivering despite normal or elevated body temperature[30].
  • Fatigue: A feeling of tiredness or exhaustion[31].
  • Nausea: An uncomfortable feeling in the stomach that may lead to vomiting[32].

These effects are generally mild and temporary, often resolving within a few hours or days after administration.

Intended Effects

It's important to understand that when rimiducid is administered, certain effects are actually intended:

  • Reduction in modified cell numbers: Rimiducid is designed to eliminate modified cells, so a decrease in their numbers is an expected and desired outcome[33].
  • Improvement in GvHD symptoms: If rimiducid is given to treat GvHD, improvement in GvHD symptoms (such as skin rash, diarrhea, or liver dysfunction) indicates the medication is working properly[34].

Special Considerations

Patients receiving rimiducid should be aware that:

  • The medication is only effective against cells that have been specifically modified to include the safety switch.
  • After rimiducid administration, the beneficial effects of the modified cells (such as anti-cancer activity) may be reduced or lost[35].
  • Close monitoring by healthcare providers is essential both before and after rimiducid administration.

Current Research and Clinical Trials

Rimiducid is being actively investigated in numerous clinical trials across various conditions and cellular therapy approaches.

Key Areas of Research

Current research focuses on:

  1. Optimizing Dosing: Studies are examining different doses of rimiducid (from 0.01 mg/kg to 0.4 mg/kg) to determine the optimal amount needed to control side effects while preserving some therapeutic benefits of the modified cells[36].

  2. Expanding Applications: Researchers are testing rimiducid-enabled safety switches in new types of cellular therapies, including:

    • Allogeneic (donor-derived) CAR-T cells for various cancers[37]
    • Natural Killer (NK) cell therapies for solid tumors[38]
    • T cell therapies for autoimmune diseases like lupus[39]

  3. Long-term Safety: Studies are following patients for up to 15 years after receiving modified cells with rimiducid-responsive safety switches to monitor for any long-term effects[40].

Notable Clinical Trials

Some significant ongoing clinical trials involving rimiducid include:

  • NCT06014762: Investigating P-CD19CD20-ALLO1 allogeneic CAR-T cells with rimiducid safety switch for B-cell malignancies[41].
  • NCT04960579: Studying P-BCMA-ALLO1 allogeneic CAR-T cells with rimiducid safety switch for multiple myeloma[42].
  • NCT05239143: Examining P-MUC1C-ALLO1 CAR-T cells with rimiducid safety switch for advanced solid tumors[43].
  • NCT06984341: Evaluating P-CD19CD20-ALLO1 for treatment-refractory systemic lupus erythematosus[44].

Future Directions

The field of cellular therapy with built-in safety mechanisms is rapidly evolving, with rimiducid playing a central role in these innovations.

Emerging Applications

Researchers are exploring several promising new applications for rimiducid-enabled safety systems:

  1. Autoimmune Disease Treatment: Using modified T cells with safety switches to target and reset the immune system in diseases like lupus, multiple sclerosis, and rheumatoid arthritis[45].

  2. Solid Tumor Therapies: Developing more effective CAR-T and CAR-NK cell therapies for solid tumors with enhanced safety profiles through rimiducid-responsive switches[46].

  3. Combination Approaches: Integrating rimiducid-enabled safety mechanisms with other emerging technologies, such as:

    • Gene editing (CRISPR/Cas9) to create more precise cell modifications
    • Controllable activation systems to turn cellular therapies "on" and "off" as needed[47]

Patient Impact

As research progresses, patients may benefit from:

  • Wider Availability: More centers offering cellular therapies with built-in safety mechanisms
  • Expanded Eligibility: More patients qualifying for these therapies due to improved safety profiles
  • Outpatient Administration: Some therapies potentially moving from inpatient to outpatient settings as safety improves[48]

Challenges to Address

Despite promising advances, several challenges remain:

  • Cost: Cellular therapies with advanced safety mechanisms are expensive to develop and administer
  • Manufacturing Complexity: Adding safety switches increases the complexity of producing modified cells
  • Balancing Safety and Efficacy: Finding the optimal approach to preserve therapeutic benefits while providing adequate safety controls[49]

Rimiducid represents an important advancement in making cellular therapies safer and more controllable, potentially expanding their application to more patients and conditions in the future.

References

  1. NCT02477878. clinicaltrials.gov.
  2. NCT03301168. clinicaltrials.gov.
  3. NCT02786485. clinicaltrials.gov.
  4. NCT03639844. clinicaltrials.gov.
  5. NCT03016377. clinicaltrials.gov.
  6. NCT03807063. clinicaltrials.gov.
  7. NCT03699475. clinicaltrials.gov.
  8. NCT03733249. clinicaltrials.gov.
  9. NCT03288493. clinicaltrials.gov.
  10. NCT02743611. clinicaltrials.gov.
  11. NCT04249947. clinicaltrials.gov.
  12. NCT02744287. clinicaltrials.gov.
  13. NCT02065869. clinicaltrials.gov.
  14. NCT03733249. clinicaltrials.gov.
  15. NCT03301168. clinicaltrials.gov.
  16. NCT03639844. clinicaltrials.gov.
  17. NCT06984341. clinicaltrials.gov.
  18. NCT03288493. clinicaltrials.gov.
  19. NCT03016377. clinicaltrials.gov.
  20. NCT03958656. clinicaltrials.gov.
  21. NCT04960579. clinicaltrials.gov.
  22. NCT06014762. clinicaltrials.gov.
  23. NCT04249947. clinicaltrials.gov.
  24. NCT02744287. clinicaltrials.gov.
  25. NCT05239143. clinicaltrials.gov.
  26. NCT01744223. clinicaltrials.gov.
  27. NCT03733249. clinicaltrials.gov.
  28. NCT03699475. clinicaltrials.gov.
  29. NCT02477878. clinicaltrials.gov.
  30. NCT02786485. clinicaltrials.gov.
  31. NCT02065869. clinicaltrials.gov.
  32. NCT03016377. clinicaltrials.gov.
  33. NCT03958656. clinicaltrials.gov.
  34. NCT03301168. clinicaltrials.gov.
  35. NCT02743611. clinicaltrials.gov.
  36. NCT03459170. clinicaltrials.gov.
  37. NCT06014762. clinicaltrials.gov.
  38. NCT07164469. clinicaltrials.gov.
  39. NCT06984341. clinicaltrials.gov.
  40. NCT03741127. clinicaltrials.gov.
  41. NCT06014762. clinicaltrials.gov.
  42. NCT04960579. clinicaltrials.gov.
  43. NCT05239143. clinicaltrials.gov.
  44. NCT06984341. clinicaltrials.gov.
  45. NCT06984341. clinicaltrials.gov.
  46. NCT06066424. clinicaltrials.gov.
  47. NCT05239143. clinicaltrials.gov.
  48. NCT06358430. clinicaltrials.gov.
  49. NCT03459170. clinicaltrials.gov.

Conditions where RIMIDUCID is being studied

Each condition opens its own overview and trial list

Malignant central nervous system neoplasmNeuroblastoma

Trials with RIMIDUCID

Recruiting trials first

See all 2 →
Quick filters

Study of GD2-CAR T Cells, Cyclophosphamide, and Fludarabine for Children with High-Risk or Relapsed Neuroblastoma and Other GD2+ Tumors

Recruiting
Registered drugNo placebo
  • Participants:All ages

Study on the Safety of Anti-GD2 CAR T Cells, Cyclophosphamide, and Fludarabine in Children and Young Adults with Relapsed or Refractory Brain Tumors

Recruiting
Registered drugNo placebo
  • Participants:All ages
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.